临床试验格局更新:2000至2020年ClinicalTrials.gov注册数据分析
该分析基于ClinicalTrials.gov的AACT数据库,纳入2000年1月1日至2020年12月31日启动的274043项注册干预性研究,描述其设计、纳入标准、干预措施、疾病和资助方特征及随时间的变化趋势。多数试验为随机(65%)、单中心(60%)、平行组(56%)、由其他来源资助(65%)和涉及药物干预(55%)。观察到的趋势包括无FDA定义分期的试验比例增加、涉及药物或以治疗为主要目的的试验比例下降、样本量和完成时间减少,以及报告结果的完成试验比例增加。
要点
- 分析纳入2000至2020年注册的274043项干预性研究。
- 65%为随机试验,60%为单中心,56%为平行组,55%涉及药物干预。
- 无FDA定义分期的试验比例随时间增加,药物或治疗目的试验比例下降。
核心结论
- 临床试验注册改变了试验信息的获取、传播和使用方式;随着试验和法规演变,注册库将继续提供获取和跟踪试验的途径,为未来试验设计提供信息并凸显该资源的价值。
研究设计与样本
- 分析公开可用的临床试验转型倡议ClinicalTrials.gov汇总分析(AACT)数据库,聚焦2000年1月1日至2020年12月31日启动的干预性研究(试验),按启动年份汇总设计、纳入标准、干预措施、疾病和资助方特征。
主要发现
- 共纳入274043项注册干预性研究。
- 多数试验报告为随机(65%)、单中心(60%)、平行组(56%)、由其他来源(如个人、大学和社区组织)资助(65%)和涉及药物干预(55%)。
- 随时间推移,无FDA定义分期的注册试验比例增加,涉及药物或报告以治疗为主要目的的试验比例下降,样本量和完成试验时间减少,完成试验中报告结果的比例增加。
- 缺失注册字段的比例随时间下降,更多试验提供方案和其他文件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical trial landscape has evolved over the last two decades, shaped by advances in therapeutics and drug development and innovation in trial design and methods. The tracking of such changes became possible with trial registration, providing the public with a window into the massive clinical research enterprise. The ClinicalTrials.gov website was launched in 2000 by the NIH National Library of Medicine and is the largest clinical trial registry worldwide. The purpose of this analysis is to describe the composition and methodologic features of clinical trials as registered on ClinicalTrials.gov and to identify trends over time. METHODS: We analyzed data from the publicly available Clinical Trials Transformation Initiative Aggregate Analysis of ClinicalTrials.gov (AACT) database, focusing on trials (interventional studies) started between 1 January 2000 through 31 December 2020. Characteristics of design (e.g., phase, randomization, use of masking, number of treatment groups, sample size), eligibility criteria (age groups, gender), interventions, conditions, and funders (primary sponsor) were tabulated over time, by year trial started. RESULTS: There were 274,043 registered interventional studies (trials) included in the analysis. Most trials were reported as randomized (65%); single site (60%); parallel-group (56%); funded by other sources (e.g., individuals, universities, and community-based organizations) (65%); and involving drug interventions (55%). Notable trends include an increase in the proportion of registered trials without FDA-defined phases ("Phase N/A") over time, a decrease in proportion of trials that involve drugs or report treatment as a primary purpose, declining sample size and time to complete trials, and an increase in proportion of trials reporting results among completed trials. The proportion of missing registration fields has also decreased over time and more trials make protocols and other documents available. There is a current need to expand the registration fields in ClinicalTrials.gov to adapt to the evolving trial designs and reduce the number of trials categorized as "other." Observed trends may be explained by changes in trial regulations as well as expanding and evolving trial designs, interventions, and outcome types. CONCLUSIONS: Clinical trial registration has transformed how trial information is accessed, disseminated, and used. As clinical trials evolve and regulations change, trial registries, including ClinicalTrials.gov, will continue to provide a means to access and follow trials over time, thus informing future trial design and highlighting the value of this tremendous resource.
引用
- Gresham G, Meinert JL, Gresham AG, et al. Update on the clinical trial landscape: analysis of ClinicalTrials.gov registration data, 2000-2020. Trials. 2022. PMID: 36203212. doi:10.1186/s13063-022-06569-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。